Immunome (NASDAQ:IMNM) Issues Earnings Results

Immunome (NASDAQ:IMNM) posted its earnings results on Tuesday. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14), FiscalAI reports.

Immunome Trading Up 6.6%

Shares of IMNM opened at $27.99 on Thursday. The firm has a market cap of $3.17 billion, a PE ratio of -11.06 and a beta of 2.08. Immunome has a 12 month low of $8.66 and a 12 month high of $28.04. The stock has a fifty day moving average price of $21.89 and a 200-day moving average price of $22.20.

Insiders Place Their Bets

In other Immunome news, Director Isaac Barchas sold 101,050 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00. Following the completion of the sale, the director owned 308,504 shares of the company’s stock, valued at approximately $6,515,604.48. This trade represents a 24.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $19.85, for a total value of $1,091,750.00. Following the sale, the insider owned 15,805 shares in the company, valued at $313,729.25. The trade was a 77.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 682,310 shares of company stock valued at $15,675,566 in the last 90 days. Corporate insiders own 7.21% of the company’s stock.

Institutional Trading of Immunome

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its stake in Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after purchasing an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after buying an additional 3,802 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of Immunome during the third quarter worth $76,000. Velan Capital Investment Management LP acquired a new stake in shares of Immunome during the third quarter worth $117,000. Finally, Quarry LP purchased a new stake in shares of Immunome during the third quarter valued at $117,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Immunome

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Truist’s higher price target and Buy rating likely supported investor enthusiasm and helped drive IMNM toward a fresh 52-week high. Truist price target update
• Positive Sentiment: Immunome reported second-quarter 2026 results and provided a business update. Investors continue to focus on the company’s clinical pipeline and progress in its antibody-based oncology and infectious-disease programs, which are central to its valuation. Immunome second-quarter 2026 results and business update
• Neutral Sentiment: Director Isaac Barchas sold 98,712 shares from August 10 through August 12 for approximately $2.6 million, reducing his direct ownership to 92,211 shares. The sales occurred under a pre-arranged Rule 10b5-1 plan, making them less conclusive as a signal of management’s current outlook. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the consensus loss estimate of $0.51. The miss highlights continued cash-burn and execution risks for the clinical-stage biotechnology company. Immunome quarterly earnings release

Wall Street Analyst Weigh In

IMNM has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Truist Financial upped their target price on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Finally, Barclays initiated coverage on Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target for the company. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.64.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.